# US 2022/0015343 A1 · Genetically modified non-human animal with human or chimeric genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0015343 A1
- Document ID: US20220015343A1
- Status: Published application
- Kind: A1
- Application number: 17/293,279
- Filed: 2019-12-17
- Published: 2022-01-20
- Earliest claimed: 2018-12-17
- Assignees: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.; Biocytogen JiangSu Co., Ltd.
- Applicants: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.; Biocytogen Jiangsu Co., Ltd.
- Inventors: Yuelei Shen; Meiling Zhang; Jiawei Yao; Chaoshe Guo; Yanan Guo; Yang Bai; Rui Huang; Lei Zhao; Chengzhang Shang
- Web page: https://patentgrep.com/patent/US20220015343A1

## CPC

- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- C07K 14/5412: {IL-6}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/248: {IL-6}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)}
- A01K 2207/15: Humanized animals
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2217/15: Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
- A01K 2227/105: Murine
- A01K 2267/0325: Animal model for autoimmune diseases
- A01K 2267/0368: Animal model for inflammation
- A61K 2039/505: {comprising antibodies}
- C12N 2015/8563: {for autoimmune diseases, e.g. Insulin-dependent diabetes mellitus}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2830/36: being a transcription termination element
- C12N 2830/60: from viruses
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) IL6R and/or IL6, and methods of use thereof.

## Claims

### Claim at position 1

-90. (canceled)

### Claim 91

A genetically-modified, non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a human interleukin-6 receptor (IL6R), wherein the sequence further comprises a Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element (WPRE).

### Claim 92 (depends on 91)

The animal of claim 91, wherein the sequence encoding the human IL6R is operably linked to an endogenous regulatory element at the endogenous IL6R gene locus in the at least one chromosome.

### Claim 93 (depends on 91)

The animal of claim 91, wherein the human IL6R comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 62.

### Claim 94 (depends on 91)

The animal of claim 91, wherein the animal comprises a sequence that is at least 80% identical to SEQ ID NO: 65.

### Claim 95 (depends on 91)

The animal of claim 91, wherein the animal is a rodent or a mouse.

### Claim 96 (depends on 91)

The animal of claim 91, wherein the animal does not express endogenous IL6R.

### Claim 97 (depends on 91)

The animal of claim 91, wherein the animal has one or more cells expressing human IL6R.

### Claim 98 (depends on 91)

The animal of claim 91, wherein 3′ end of the sequence is linked to an endogenous sequence starting at the first G of GCTGC in SEQ ID NO: 67.

### Claim 99 (depends on 91)

The animal of claim 91, wherein the animal further comprises a sequence encoding human or chimeric IL6.

### Claim 100

A genetically-modified, non-human animal whose genome comprises at least one chromosome comprising a sequence encoding a human IL6 at an endogenous IL6 gene locus.

### Claim 101 (depends on 100)

The animal of claim 100, wherein the sequence encoding the human IL6 is operably linked to an endogenous regulatory element at the endogenous IL6 gene locus in the at least one chromosome.

### Claim 102 (depends on 100)

The animal of claim 100, wherein the sequence encoding the human IL6 is operably linked to a human regulatory element at the endogenous IL6 gene locus in the at least one chromosome.

### Claim 103 (depends on 100)

The animal of claim 100, wherein the human IL6 comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 6 or SEQ ID NO: 8.

### Claim 104 (depends on 100)

The animal of claim 100, wherein the animal is a rodent or a mouse.

### Claim 105 (depends on 100)

The animal of claim 100, wherein the animal has a B-NDG (NOD-Prkdscid L-2rgnull) or C57/BL6 background.

### Claim 106 (depends on 100)

The animal of claim 100, wherein the animal does not express endogenous IL6.

### Claim 107 (depends on 100)

The animal of claim 100, wherein the animal has one or more cells expressing human IL6.

### Claim 108 (depends on 100)

The animal of claim 100, wherein the animal further comprises a sequence encoding human or chimeric IL6R.

### Claim 109

A method of producing a genetically-modified rodent, the method comprising
modifying a genome of an embryo of a rodent by CRISPR associate protein 9 (Cas9) with sgRNAs that target SEQ ID NO: 26 and SEQ ID NO: 34 and a targeting vector, thereby generating a genome in the embryo that comprises at least one chromosome comprising a sequence encoding a chimeric IL6, wherein the targeting vector comprises a 5′ homologous arm, a 3′ homologous arm, and a human IL6 gene fragment; and
transplanting the embryo to a recipient rodent to produce a genetically-modified rodent.

### Claim 110 (depends on 109)

The method of claim 109, wherein the rodent is a mouse.
